Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Tjoung-Won Park-Simon, Gordon Rustin, Florence Joly, Mansoor R Mirza, Marie Plante, Michael Quinn, Andrés Poveda, Gordon C Jayson, Dan Stark, Ann Marie Swart, Laura Farrelly, Richard Kaplan, Mahesh K B Parmar, Timothy J Perren

Open source

DOI: 10.1016/s1470-2045(15)00086-8
Published: 2015-08
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-15-00086-8,
  title = {Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial},
  author = {Amit M Oza and Adrian D Cook and Jacobus Pfisterer and Andrew Embleton and Jonathan A Ledermann and Eric Pujade-Lauraine and Gunnar Kristensen and Mark S Carey and Philip Beale and Andrés Cervantes and Tjoung-Won Park-Simon and Gordon Rustin and Florence Joly and Mansoor R Mirza and Marie Plante and Michael Quinn and Andrés Poveda and Gordon C Jayson and Dan Stark and Ann Marie Swart and Laura Farrelly and Richard Kaplan and Mahesh K B Parmar and Timothy J Perren},
  year = {2015},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(15)00086-8},
  url = {https://doi.org/10.1016/s1470-2045(15)00086-8}
}

RIS

TY  - JOUR
TI  - Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AU  - Amit M Oza
AU  - Adrian D Cook
AU  - Jacobus Pfisterer
AU  - Andrew Embleton
AU  - Jonathan A Ledermann
AU  - Eric Pujade-Lauraine
AU  - Gunnar Kristensen
AU  - Mark S Carey
AU  - Philip Beale
AU  - Andrés Cervantes
AU  - Tjoung-Won Park-Simon
AU  - Gordon Rustin
AU  - Florence Joly
AU  - Mansoor R Mirza
AU  - Marie Plante
AU  - Michael Quinn
AU  - Andrés Poveda
AU  - Gordon C Jayson
AU  - Dan Stark
AU  - Ann Marie Swart
AU  - Laura Farrelly
AU  - Richard Kaplan
AU  - Mahesh K B Parmar
AU  - Timothy J Perren
PY  - 2015
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(15)00086-8
UR  - https://doi.org/10.1016/s1470-2045(15)00086-8
ER  -

APA

Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T., Rustin, G., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A., Jayson, G. C., Stark, D., Swart, A. M., Farrelly, L., Kaplan, R., Parmar, M. K. B., & Perren, T. J. (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00086-8

Source records

crossref · retrieved 2026-09-26T13:34:28.005Z